Welcome to our dedicated page for Teva Pharm SEC filings (Ticker: TEVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Teva Pharmaceutical Industries Limited (TEVA) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and other key documents filed with the Securities and Exchange Commission. As an issuer with American Depositary Shares listed on the New York Stock Exchange under the symbol TEVA, Teva reports material events, financing arrangements and financial results through these filings.
Recent Form 8‑K filings include items on results of operations and financial condition, where Teva furnishes press releases announcing quarterly financial results for periods such as the quarters ended June 30 and September 30. These filings typically incorporate earnings press releases by reference and clarify that the information is being furnished rather than filed for purposes of the Exchange Act. Another 8‑K describes Teva’s presentation at a major healthcare conference and includes expectations regarding performance for the 2025 fiscal year.
Teva also uses Form 8‑K to disclose material definitive agreements and related direct financial obligations. For example, an 8‑K details the Third Amendment to the Senior Unsecured Sustainability-Linked Revolving Credit Agreement, which extended the maturity date of the revolving facility and amended financial covenants such as the maximum leverage ratio and conditions tied to investment grade status. These filings provide insight into Teva’s capital structure, liquidity management and covenant framework.
On Stock Titan, investors can review these filings alongside AI-powered summaries that explain the main points of each document in plain language. This includes highlighting key terms in credit agreements, summarizing earnings-related disclosures, and pointing out items that may affect leverage, liquidity or future reporting. Users interested in TEVA can use the filings page to track quarterly and annual reporting, current reports on material events, and disclosures related to financing arrangements, while AI tools help interpret lengthy or technical sections of the filings.
Teva Pharmaceutical Industries executive Matthew Shields exercised 17,295 restricted share units into ordinary shares and, on the same day, sold 17,295 ordinary shares in an open-market transaction at a weighted average price of $31.6684. The sale was executed under a Rule 10b5-1 trading plan adopted on November 10, 2025 and included shares sold to cover tax withholding obligations tied to vesting. Following these transactions, Shields directly holds 9,989 ordinary shares and 51,887 restricted share units.
Teva Pharmaceutical Industries President and CEO Richard Francis reported multiple equity transactions on ordinary shares and restricted share units. He exercised 50,223 restricted share units, receiving the same number of ordinary shares at a price of
On the same date, he received a new award of 136,736 restricted share units, each representing a right to one ordinary share or its cash value at settlement. He then sold 23,393 ordinary shares at a weighted average price of
Following these transactions, Francis held 1,148,212 ordinary shares directly.
Teva Pharmaceutical Industries EVP, Europe Commercial Daniell Richard reported a combination of equity awards, vesting and share sales. On March 4, 2026, he exercised restricted share units into 33,512 and 20,461 ordinary shares and received a new grant of 33,424 restricted share units.
He then sold 91,345 ordinary shares in open-market transactions at weighted average prices of $32.4645 and $32.9474, executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 10, 2025. Following these trades, he directly owned 85,755 ordinary shares. The filing notes the sales related to vesting of restricted share units, including shares sold to cover tax withholding obligations.
Jover Placid reported acquisition or exercise transactions in this Form 4 filing.
TEVA PHARMACEUTICAL INDUSTRIES LTD reported that officer Jover Placid received a grant of 37,982 restricted share units on March 4, 2026. Each restricted share unit represents a contingent right to receive one ordinary share, or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share.
The award vests in four annual installments, with 9,495 units vesting on each of March 4, 2027, March 4, 2028, and March 4, 2029, and 9,497 units vesting on March 4, 2030. The ordinary shares may be represented by American Depositary Shares, each currently corresponding to one ordinary share.
TEVA PHARMACEUTICAL INDUSTRIES LTD reported that EVP, Global Operations Matthew Shields acquired 33,424 restricted share units as a grant on March 4, 2026. Each restricted share unit represents a contingent right to receive one ordinary share or, at the committee’s option, the cash value of one ordinary share.
The award vests in four equal installments of 8,356 units on March 4 of 2027, 2028, 2029, and 2030. The filing notes that the company’s ordinary shares may be represented by American Depositary Shares, and that each ADS currently represents one ordinary share.
TEVA PHARMACEUTICAL INDUSTRIES LTD officer Mark Sabag reported equity compensation activity involving restricted share units and ordinary shares. On March 4, 2026, he exercised restricted share units into 33,512 ordinary shares and 18,601 ordinary shares at a price of zero per share, increasing his direct holdings. He also received a new grant of 30,385 restricted share units, scheduled to vest in annual installments from March 4, 2027 through March 4, 2030. Each restricted share unit represents a right to one ordinary share or its cash value, and the ordinary shares may be represented by American Depositary Shares.
Lippman Evan reported acquisition or exercise transactions in this Form 4 filing.
Teva Pharmaceutical Industries executive Evan Lippman, EVP of Business Development, received a grant of 27,347 restricted share units (RSUs) on March 4, 2026. Each RSU represents a contingent right to receive either one ordinary share or, at the compensation committee’s option, the cash value of one ordinary share.
The RSUs vest in four annual installments: 6,836 on each of March 4, 2027, March 4, 2028, and March 4, 2029, and 6,839 on March 4, 2030. Following this award, Lippman’s reported derivative holdings from this grant total 27,347 RSUs. The filing notes that Teva’s ordinary shares may be represented by American Depositary Shares, each currently equal to one ordinary share.
TEVA PHARMACEUTICAL INDUSTRIES LTD executive Eric A. Hughes reported RSU vesting, a new RSU grant, and a small share sale. On March 4, 2026, he exercised 23,251 restricted share units into the same number of ordinary shares at $0.00 per share and received a new award of 50,643 restricted share units.
He then sold 11,277 ordinary shares at a weighted average price of $32.4645 per share in an open-market transaction effected under a Rule 10b5-1 trading plan, with the footnotes stating this sale was to cover tax withholding from the RSU vesting. After these transactions, he directly held 97,590 ordinary shares and 50,643 restricted share units, each RSU representing a contingent right to one ordinary share or its cash value at settlement.
Teva Pharmaceutical Industries executive vice president and chief financial officer Eliyahu Sharon Kalif reported equity compensation activity involving restricted share units and ordinary shares. On March 4, 2026, he exercised previously granted restricted share units into 33,512 ordinary shares and 23,251 ordinary shares at a price of $0.00 per share, reflecting the settlement of vested awards. The filing also shows a new grant of 53,175 restricted share units, each representing a contingent right to receive one ordinary share or its cash value. Following these transactions, his directly owned ordinary shares increased to 305,519. Footnotes describe multi‑year vesting schedules for the 2022, 2024, and 2026 restricted share unit grants, with installments vesting annually through March 4, 2030, and clarify that ordinary shares may be represented by American Depositary Shares on a one‑to‑one basis.
Teva Pharmaceutical Industries EVP U.S. Commercial Christine Fox reported RSU vesting, a new RSU grant, and a related share sale. On March 4, 2026 she acquired 20,461 ordinary shares through the exercise of restricted share units and received a grant of 50,643 restricted share units. She then sold 9,098 ordinary shares at a weighted average price of $32.4645 pursuant to a Rule 10b5-1 trading plan, with the sale representing shares required to cover tax withholding from the RSU vesting, leaving her with 75,010 ordinary shares held directly.